Skip to main content
 

Press Releases

July 25, 2017
Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence of multiple groups readily applying CRISPR/Cas9 gene editing to eukaryotic cells following teachings of Charpentier-Doudna team
July 6, 2017

BERKELEY, CA– July 6, 2017 – Caribou Biosciences, Inc., a leading genome engineering company, announced today that Steven B. Kanner, Ph.D. has joined the Company as Chief Scientific Officer. Dr. Kanner brings more than 25 years of experience in drug discovery and development and will lead Caribou’s research and development of new applications for its gene editing technology.

May 10, 2017
Patent covers foundational CRISPR-Cas9 inventions for which Caribou holds an exclusive license from the University of California and the University of Vienna Claims cover CRISPR-Cas9 compositions for use in any non-cellular and cellular setting, including eukaryotic cells
May 2, 2017

BERKELEY, Calif.--(BUSINESS WIRE)--Caribou Biosciences, Inc., a leading company in CRISPR-Cas genome engineering, today announced that the United States Patent and Trademark Office (USPTO) has granted Vilnius University a CRISPR-Cas9 genome editing patent. Caribou has rights to this intellectual property in multiple fields of use, including exclusive access in the research tools field. Caribou gained these rights as part of its worldwide cross-license agreement with DuPont Company, to which Vilnius University exclusively licensed this intellectual property.

May 1, 2017
Breakthrough method will allow researchers to identify CRISPR-Cas9 targets and delivery methods with the highest activity and specificity Caribou and DuPont Pioneer scientists publish paper in Nature Methods describing SITE-Seq

Pages